UTHR Q2 2022 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$467M+4.6% YoY

Gross Profit

$437M93.6% margin

Operating Income

$202M43.2% margin

Net Income

$116M24.8% margin

EPS (Diluted)

$2.41

QoQ Revenue Growth

+1.1%

Cash Flow

Operating Cash Flow

$127M

Free Cash Flow

$110M

Stock-Based Comp.

$66M

Balance Sheet

Total Assets

$5.5B

Total Liabilities

$1.2B

Stockholders' Equity

$4.3B

Cash & Equivalents

$795M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$467M	$447M	+4.6%
Gross Profit	$437M	$409M	+6.8%
Operating Income	$202M	$222M	-9.2%
Net Income	$116M	$173M	-32.8%

Revenue Segments

Tyvaso

$201M43%

Remodulin

$132M28%

Orenitram

$79M17%

Unituxin

$45M10%

Adcirca

$10M2%

Geographic Segments

UNITED STATES

$440M94%

Non-US

$27M6%